The pharmacokinetics of Casodex in laboratory animals

Xenobiotica. 1991 Oct;21(10):1347-55. doi: 10.3109/00498259109043209.

Abstract

1. The pharmacokinetics of Casodex, a novel, non-steroidal antiandrogen, have been investigated following single oral and i.v. doses and during daily oral dosing to male and female rats and male dogs. 2. The binding of 14C-Casodex to rat, dog and human plasma proteins, determined by equilibrium dialysis, was high with values greater than 95%; in dog there was evidence for decreased binding at concentrations greater than 12 micrograms/ml. 3. Casodex was slowly absorbed over prolonged periods and its bioavailability decreased with increase in dose from 72% and 88% in male and female rats respectively at 1 mg/kg to 10% and 12% at 250 mg/kg; in dog bioavailability decreased from 100% at 0.1 mg/kg to 31% at 100 mg/kg. 4. Elimination of Casodex from plasma was slow with terminal elimination half-lives of about 1 day in rat and about 6 days in dog. On daily administration to rats Casodex accumulates slightly in plasma at 10 mg/kg but not at 250 mg/kg; in dog appreciable accumulation (9-12-fold), calculated from the ratio of trough plasma concentrations at steady state to those after a single dose, was observed at 2.5 and 10 mg/kg, but at 100 mg/kg the accumulation ratio was much lower (4-fold).

MeSH terms

  • Administration, Oral
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / blood
  • Androgen Antagonists / pharmacokinetics
  • Anilides / administration & dosage
  • Anilides / blood
  • Anilides / pharmacokinetics*
  • Animals
  • Blood Proteins / metabolism
  • Dogs
  • Female
  • Half-Life
  • Injections, Intravenous
  • Male
  • Metabolic Clearance Rate
  • Nitriles
  • Protein Binding
  • Rats
  • Rats, Inbred Strains
  • Tosyl Compounds

Substances

  • Androgen Antagonists
  • Anilides
  • Blood Proteins
  • Nitriles
  • Tosyl Compounds
  • bicalutamide